MBRX

Companies
NASDAQ
Moleculin Biotech Inc.
Health Care
Price Chart
Overview

About MBRX

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Market Cap
$10.0M
Volume
284.5K
Avg. Volume
214.7K
P/E Ratio
-0.16013628
Dividend Yield
0.00%
Employees
19.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
1.07
Moderate Correlation
Volatility
High (1.00)
Relative to market
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for MBRX.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, MBRX shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$10.0M
Volume284.5K
P/E Ratio-0.16
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 14, 2025

PortfolioPilot Analysis

Get AI-powered insights on how MBRX fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025